BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 30551958)

  • 21. Efficacy of intraperitoneal and intravenous chemotherapy for advanced gastric cancer with peritoneal metastasis.
    Chen Y; Wang XJ; Lin RB; Chen L; Lin G; Guo ZQ
    Tumori; 2014; 100(5):e180-8. PubMed ID: 25343556
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase II, randomised study of mFOLFOX6 with or without the Akt inhibitor ipatasertib in patients with locally advanced or metastatic gastric or gastroesophageal junction cancer.
    Bang YJ; Kang YK; Ng M; Chung HC; Wainberg ZA; Gendreau S; Chan WY; Xu N; Maslyar D; Meng R; Chau I; Ajani JA
    Eur J Cancer; 2019 Feb; 108():17-24. PubMed ID: 30592991
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A prognostic model in patients treated for metastatic gastric cancer with second-line chemotherapy.
    Kanagavel D; Pokataev IA; Fedyanin MY; Tryakin AA; Bazin IS; Narimanov MN; Yakovleva ES; Garin AM; Tjulandin SA
    Ann Oncol; 2010 Sep; 21(9):1779-1785. PubMed ID: 20150573
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Docetaxel monotherapy as a second-line treatment after failure of fluoropyrimidine and platinum in advanced gastric cancer: experience of 154 patients with prognostic factor analysis.
    Jo JC; Lee JL; Ryu MH; Sym SJ; Lee SS; Chang HM; Kim TW; Lee JS; Kang YK
    Jpn J Clin Oncol; 2007 Dec; 37(12):936-41. PubMed ID: 18211985
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcomes of colorectal cancer patients with peritoneal carcinomatosis treated with chemotherapy with and without targeted therapy.
    Klaver YL; Simkens LH; Lemmens VE; Koopman M; Teerenstra S; Bleichrodt RP; de Hingh IH; Punt CJ
    Eur J Surg Oncol; 2012 Jul; 38(7):617-23. PubMed ID: 22572106
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of histological regression grade after two neoadjuvant approaches with or without radiotherapy in locally advanced gastric cancer.
    Martin-Romano P; Sola JJ; Diaz-Gonzalez JA; Chopitea A; Iragorri Y; Martínez-Regueira F; Ponz-Sarvise M; Arbea L; Subtil JC; Cano D; Ceniceros L; Legaspi J; Hernandez JL; Rodríguez J
    Br J Cancer; 2016 Sep; 115(6):655-63. PubMed ID: 27537382
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic factors in first-line chemotherapy treated metastatic gastric cancer patients: a retrospective study.
    Inal A; Kaplan MA; Kuçukoner M; Urakci Z; Guven M; Nas N; Yunce M; Işikdogan A
    Asian Pac J Cancer Prev; 2012; 13(8):3869-72. PubMed ID: 23098485
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adjuvant chemotherapy with S-1 followed by docetaxel for gastric cancer and CY1P0 peritoneal metastasis after relatively curative surgery.
    Kanazawa Y; Kato S; Fujita I; Onodera H; Uchida E
    J Nippon Med Sch; 2013; 80(5):378-83. PubMed ID: 24189356
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correlation between microRNA-766 expression in patients with advanced gastric cancer and the efficacy of platinum-containing chemotherapy.
    Xue YF; Xue D; Yao B; Hu CG; Liu J
    Eur Rev Med Pharmacol Sci; 2020 Sep; 24(17):8822-8829. PubMed ID: 32964970
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical management patterns of advanced and metastatic gastro-oesophageal carcinoma after fluoropyrimidine/platinum treatment in France, Germany, Spain and the United Kingdom.
    Brown J; Liepa AM; Bapat B; Madhwani S; Lorenzen S; García-Foncillas J; Candrilli SD; Kaye JA
    Eur J Cancer Care (Engl); 2020 Mar; 29(2):e13213. PubMed ID: 31883156
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial.
    Winther SB; Liposits G; Skuladottir H; Hofsli E; Shah CH; Poulsen LØ; Ryg J; Osterlund P; Berglund Å; Qvortrup C; Glimelius B; Sorbye H; Pfeiffer P
    Lancet Gastroenterol Hepatol; 2019 May; 4(5):376-388. PubMed ID: 30852136
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The influence of prior ramucirumab treatment on the clinical activity of FOLFIRI as third-line therapy in patients with metastatic gastric Cancer.
    Roviello G; Petrioli R; Rosellini P; Multari AG; Conca R; Paganini G; Chiriacò G; Aieta M
    Invest New Drugs; 2019 Jun; 37(3):524-530. PubMed ID: 30687871
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) as a third-line chemotherapy treatment in metastatic gastric cancer, after failure of fluoropyrimidine, platinum, anthracycline, and taxane.
    Erdem GU; Bozkaya Y; Ozdemir NY; Demirci NS; Yazici O; Zengin N
    Bosn J Basic Med Sci; 2018 May; 18(2):170-177. PubMed ID: 28941466
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and Safety of FOLFIRI Regimen in Elderly Versus Nonelderly Patients with Metastatic Colorectal or Gastric Cancer.
    Kim JW; Lee KW; Kim KP; Lee JH; Hong YS; Kim JE; Kim SY; Park SR; Nam BH; Cho SH; Chung IJ; Park YS; Oh HS; Lee MA; Kang HJ; Park YI; Song EK; Han HS; Lee KT; Shin DB; Kang JH; Zang DY; Kim JH; Kim TW
    Oncologist; 2017 Mar; 22(3):293-303. PubMed ID: 28209749
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study.
    Rao S; Starling N; Cunningham D; Sumpter K; Gilligan D; Ruhstaller T; Valladares-Ayerbes M; Wilke H; Archer C; Kurek R; Beadman C; Oates J
    Ann Oncol; 2010 Nov; 21(11):2213-2219. PubMed ID: 20497967
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of squamous cell carcinoma of external auditory canal: A tertiary cancer centre experience.
    Gandhi AK; Roy S; Biswas A; Raza MW; Saxena T; Bhasker S; Sharma A; Thakar A; Mohanti BK
    Auris Nasus Larynx; 2016 Feb; 43(1):45-9. PubMed ID: 26165629
    [TBL] [Abstract][Full Text] [Related]  

  • 37. EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
    Wagner AD; Grabsch HI; Mauer M; Marreaud S; Caballero C; Thuss-Patience P; Mueller L; Elme A; Moehler MH; Martens U; Kang YK; Rha SY; Cats A; Tokunaga M; Lordick F
    BMC Cancer; 2019 May; 19(1):494. PubMed ID: 31126258
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Docetaxel/cisplatin followed by FOLFIRI versus the reverse sequence in metastatic gastric cancer.
    Kim JA; Lee J; Han B; Park SH; Park JO; Park YS; Lim HY; Kang WK
    Cancer Chemother Pharmacol; 2011 Jul; 68(1):177-84. PubMed ID: 20878159
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with lobaplatin and docetaxel to treat synchronous peritoneal carcinomatosis from gastric cancer: Results from a Chinese center.
    Wu HT; Peng KW; Ji ZH; Sun JH; Zhang Q; Yang XJ; Huang CQ; Li Y
    Eur J Surg Oncol; 2016 Jul; 42(7):1024-34. PubMed ID: 27179924
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II study of biweekly paclitaxel plus infusional 5-fluorouracil and leucovorin as first-line chemotherapy in patients with advanced gastric cancer.
    Wang F; Wang Z; Zhou N; An X; Xu R; He Y; Li Y
    Am J Clin Oncol; 2011 Aug; 34(4):401-5. PubMed ID: 21791984
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.